Trending Now
UNITY Biotechnology Inc. (NASDAQ: UBX) Announce Findings of First Phase UBX1325...
UNITY Biotechnology Inc. (NASDAQ: UBX) has announced that 24-week clinical findings from the first phase trial of UBX1325 were presented at the Bascom Palmer...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
S&P 500 (VIX) dips in pre market session for another blood...
Futures are down big this morning. The SPY is currently sitting at 306.10 in the premarket and it’s right above the pre-market...
MAKE IT MODERN
LATEST REVIEWS
NRx Pharmaceuticals (NASDAQ: NRXP) Announces More Findings In ZYESAMI Evaluation in...
NRx Pharmaceuticals (NASDAQ: NRXP) has announced an additional finding in the Phase 2b/3 clinical study evaluating ZYESAMI (aviptadil) in Critical COVID-19 induced acute respiratory failure...
MAKE IT MODERN
PERFORMANCE TRAINING
Dynavax Technologies’(NASDAQ:DVAX) Appoints Peter Paradiso To Board And Its CFO To Retire In 2021
Dynavax Technologies Corporation (NASDAQ:DVAX) has appointed Peter R. Paradiso to the Board of Directors and also announced that its SVP, CFO, and Chief Business...
MyoKardia Inc. (NASDAQ:MYOK) Reports Q3 2020 Financial Results and Announced Partnership With LianBio
MyoKardia Inc. (NASDAQ:MYOK) has reported its financial results for the three months ended September 30, 2020.
MyoKardia enters partnership with LianBio
The company entered a strategic...
Ambrx Biopharma Inc ($AMAM) rally could continue as biotech sector heats up
Ambrx Biopharma Inc (NYSE: AMAM) stock surged more than 1000% on Friday after the biotech company announced preliminary safety and efficacy data from...
Kiniksa Pharmaceuticals Ltd’s (NASDAQ: KNSA) Phase 3 Part Of Phase 2/3 Mavrilimumab Failed To...
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) has announced that the third phase part of the Phase 2/3 mavrilimumab study in COVID-19 related acute respiratory syndrome...
Atossa Therapeutics Inc (NASDAQ: ATOS) Granted Regulatory Approval To Open Clinical Study of AT-H201...
Atossa Therapeutics Inc (NASDAQ: ATOS) announced that the company had received regulatory approval to open a clinical study of AT-H201 in Australia. Human Research...
MAKE IT MODERN
